Company Description
Alumis Inc., a clinical stage biopharmaceutical company, focuses on identifying, acquiring, and accelerating the development and commercialization of medicines for autoimmune disorders.
The company’s clinical asset comprises of ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor which is in Phase 3 clinical trials for the treatment of plaque psoriasis, systemic lupus erythematosus, and non-infectious uveitis; A-005, a central nervous system-penetrant allosteric TYK2 inhibitor which is in Phase 1 clinical trials for neuroinflammatory and neurodegenerative diseases; and interferon regulatory factor 5 (IRF5) which is in preclinical phase to address immune dysfunction.
The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022.
The company was incorporated in 2021 and is headquartered in South San Francisco, California.
| Country | United States |
| Founded | 2021 |
| IPO Date | Jun 28, 2024 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 170 |
| CEO | Martin Babler |
Contact Details
Address: 280 East Grand Avenue South San Francisco, California 94080 United States | |
| Phone | 650 231 6625 |
| Website | alumis.com |
Stock Details
| Ticker Symbol | ALMS |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 0001847367 |
| CUSIP Number | 022307102 |
| ISIN Number | US0223071020 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Martin Babler Ph.D. | President, Chief Executive Officer and Chairman |
| Dr. David M. Goldstein Ph.D. | Chief Scientific Officer |
| Roy C. Hardiman J.D. | Chief Business and Strategy Officer |
| John R. Schroer C.F.A. | Chief Financial Officer |
| Sara Klein | Chief Legal Officer and Corporate Secretary |
| Derrick Richardson | Senior Vice President of People and Culture |
| Claire Langrish Ph.D. | Senior Vice President and Head of Immunology and Translational Science |
| Philip Nunn Ph.D. | Senior Vice President of Pharmacology and Project Team Leader |
| Dr. Jorn Drappa M.D., Ph.D. | Chief Medical Officer |
| Mark Bradley | Chief Development Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 27, 2025 | S-4 | Filing |
| Mar 25, 2025 | 8-K | Current Report |
| Mar 19, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 19, 2025 | 10-K | Annual Report |
| Mar 19, 2025 | 8-K | Current Report |
| Mar 18, 2025 | 8-K | Current Report |
| Mar 10, 2025 | 8-K | Current Report |
| Mar 4, 2025 | 8-K | Current Report |
| Feb 21, 2025 | 8-K | Current Report |
| Feb 14, 2025 | DRS | [Cover] Draft Registration Statement |